Blogs
Healthcare and Medtech Research Reports
Sep 14, 2026
Summary Novartis faced an unusually difficult period in late August–September 2026, with two Phase 3 programs (pelacarsen and del-desiran) failing their primary endpoints and eight rap-cel autoimmune trials paused following three patient deaths. The back-to-back setbacks triggered a sharp market response, wi...
Read More...
Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer
Aug 05, 2026
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper